



SOCIEDADE BRASILEIRA
DE DERMATOLOGIA

Anais Brasileiros de Dermatologia

www.anaisdedermatologia.org.br



IMAGES IN DERMATOLOGY

Scanning electron microscopy of panitumumab-induced eyelash and hair alterations – Pili canaliculi*



Debora Sarzi Sartori ^{a,b}, Antônia Larangeira de Almeida ^c,
Gabriel Santana Pereira de Oliveira ^c, Hiram Larangeira de Almeida Jr ^{a,b,*}

^a Post-graduation Program in Health, Universidade Católica de Pelotas, Pelotas, RS, Brazil

^b Department of Dermatology, Universidade Federal de Pelotas, Pelotas, RS, Brazil

^c Dermatology League, Universidade Federal de Pelotas, Pelotas, RS, Brazil

Received 9 March 2021; accepted 21 March 2021

Available online 15 January 2022

KEYWORDS

Microscopy, electron;
Panitumumab;
Scalp dermatoses

Abstract Panitumumab is a monoclonal antibody against the epidermal growth factor receptor used in metastatic colorectal cancer; in addition to tumor cells, it acts on epidermal keratinocytes and on the outer root sheath and presents skin toxicity in up to 90% of cases. A scanning electron microscope was used to examine the eyelashes and hairs of a 65-year-old patient with eyelash trichomegaly, curly hair, and paronychia undergoing treatment with panitumumab. Grooving in the hair shafts were identified, which were more evident in the eyelashes. Similar to oral epidermal growth factor inhibitors (erlotinib and gefitinib), panitumumab can cause acquired pili canaliculi.

© 2021 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Epithelial growth factor (EGF) inhibitors are considered essential for the treatment of several epithelial tumors and are part of the list of target therapies, as they

act on a specific signaling pathway and therefore have a better adverse effects profile when compared to conventional chemotherapy.¹ They can be small molecules for oral use, acting intracellularly, such as erlotinib and gefitinib, and also immunobiologics targeting the receptor itself (EGFR), such as panitumumab and cetuximab. Among the skin adverse effects papulopustular eruptions are the most frequent,^{2,3} in addition to pruritus, xerosis, periungual pyogenic granuloma, eyelash trichomegaly, hair thickening, and curling.^{4,5}

* Study conducted at the Pós-Graduação em Saúde e Comportamento, Universidade Católica de Pelotas and Liga de Dermatologia da Universidade Federal de Pelotas, Pelotas, RS, Brazil.

* Corresponding author.

E-mail: hiramalmeidajr@hotmail.com (H.L. Almeida Jr.).




Figure 1 Scanning electron microscopy - Eyelash examination - small (A) and medium magnification (B), showing grooves in the hair shaft ($\times 180$, $\times 330$).

Panitumumab is a fully human anti-EGFR monoclonal antibody used primarily to treat metastatic colorectal cancer. However, in addition to its action on tumor cells, it also acts on other tissues that have EGFR expression, particularly on the keratinocytes in the basal layer of the epidermis and in the outer sheath of hair follicles, leading to skin toxicity in up to 90% of cases.⁶

Although there have been reports describing the ultrastructural aspects of hair secondary to oral EGFR inhibitors, such as gefitinib⁷ and erlotinib,⁸ there are no reports of electron microscopy analysis of these effects on hair shafts with monoclonal antibodies that inhibit this receptor.

Case report

This case report describes a 65-year-old male patient with a malignant colorectal neoplasm. Surgical treatment with hemicolectomy and adjuvant chemotherapy was performed. A year later, he started another chemotherapy regimen due to the appearance of liver metastases; however, this treatment was not effective, so treatment with panitumumab was initiated. After six months of treatment, the patient showed pyogenic periungual granulomas and eyelash alterations, which became elongated and straightened, requiring cutting for aesthetic reasons, his hair became slightly curly and rougher to the touch. Eyelash and hair fragments were collected by cutting them with scissors for *in natura* analysis using scanning electron microscopy.

The eyelash examination showed well-developed grooves at medium magnifications (Fig. 1), high magnifications showed cuticle disorganization, in addition to the grooving, and some hair shafts had more than one groove (Fig. 2). Examination of head hairs also revealed grooves (Fig. 3) at




Figure 2 Scanning Electron Microscopy – Eyelash examination – (A), high magnification, showing grooving in the hair shaft and cuticle irregularity ($\times 450$). (B), High magnification, showing two grooves in the hair shaft – arrows ($\times 700$).

small and medium magnifications, less evident than in the eyelashes. High magnifications showed slight cuticle disorganization (Fig. 4).

Discussion

The ultrastructural findings observed secondary to the use of panitumumab are similar to those previously described for erlotinib and gefitinib, in which grooving was described and classified as pili canaliculi. In the case of erlotinib, eyelash trichomegaly and curly hairs, were seen, ultrastructurally grooves and hair twisting were observed. In the reported case of gefitinib use, the alterations were subclinical with discrete grooving. The case investigated here had important eyelash trichomegaly, with more discreet alterations of head hairs, both clinically and on ultrastructural examination. Panitumumab prolongs the anagen phase, hence the occurrence of trichomegaly, with more evident effects on the eyelashes.

These findings demonstrate that the ultrastructural aspects of hair follicle changes by EGF inhibition are independent of the inhibition pathway. Both intracellular tyrosine kinase inhibition by oral small molecules and com-




Figure 3 Scanning electron microscopy - Hair examination - small (A) and medium magnification (B), showing grooves in the hair shaft ($\times 45$, $\times 250$).




Figure 4 Scanning electron microscopy - Hair examination - large magnification showing slight cuticle disorganization ($\times 900$).

petitive inhibition of the EGFR binding site on the cell surface with monoclonal antibodies, produce similar ultrastructural alterations.

Financial support

None declared.

Authors' contributions

Debora Sarzi Sartori: Approval of the final version of the manuscript; design and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; critical review of the manuscript.

Antônia Larangeira de Almeida: Approval of the final version of the manuscript; drafting and editing of the manuscript; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; critical review of the manuscript.

Gabriel Santana Pereira de Oliveira: Approval of the final version of the manuscript; drafting and editing of the manuscript; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; critical review of the manuscript.

Hiram de Almeida Jr: Approval of the final version of the manuscript; design and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; effective participation in research orientation; intellectual participation in the propaedeutic and/or therapeutic conduct of the studied cases; critical review of the literature; critical review of the manuscript.

Conflicts of interest

None declared.

References

1. Holcman M, Sibilia M. Mechanisms underlying skin disorders induced by EGFR inhibitors. *Mol Cell Oncol.* 2015;2:1–10.
2. Rodarte CM, Abdallah OA, Barbosa NF, Koch LO, Resende UM. Cutaneous reactions due to the use of epidermal growth factor receptor inhibitors: two case reports. *An Bras Dermatol.* 2009;84:667–70.
3. Santiago F, Gonçalo M, Reis JP, Figueiredo A. Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients. *An Bras Dermatol.* 2011;86:483–90.
4. McGregor M, Price TJ. Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC. *Future Oncol.* 2018;14:2437–59.
5. Kremer N, Martinez H, Leshem YA, Hodak E, Zer A, Brenner B, et al. The trichoscopic features of hair shaft anomalies induced by epidermal growth factor receptor inhibitors: A case series. *J Am Acad Dermatol.* 2020;90:30477.
6. Morris LGT, Hochster HS, DeLacure MD. Eyelash trichomegaly secondary to panitumumab therapy. *Curr Oncol.* 2011;18:145–6.
7. Almeida Jr HL, Sartori DS, Almeida AL, Ruas CP, Zerwes G. Scanning Electron Microscopy of Subclinical Gefitinib-Induced Hair Changes. *Int J Trichology.* 2020;13:129–31.
8. Almeida Jr HL, Sartori DS, Deves RP, Cruz OM. Scanning Electron Microscopy of Erlotinib-induced Hair Changes: Pili Torti et Canaliculi. *Int J Trichology.* 2019;11:238–40.